Cardiovascular Revascularization Medicine Cardiovascular Revascularization Medicine RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cost-Effectiveness Analysis of the Orbital Atherectomy System: Two-Year Follow-up
This study aimed to evaluate cost-effectiveness of OAS compared to standard treatment. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 13, 2016 Category: Cardiology Authors: Louis P. Garrison, Marita R. Zimmermann, Christopher H. Young, Janna Crittendon, Philippe G énéreux Source Type: research

Long-Term Follow-Up After Near-Infrared Spectroscopy Coronary Imaging: Insights from the Lipid cORe Plaque Association With CLinical Events (ORACLE-NIRS) Registry
Coronary lipid core plaque may be associated with the incidence of subsequent cardiovascular events. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 13, 2016 Category: Cardiology Authors: Barbara Anna Danek, Aris Karatasakis, Judit Karacsonyi, Aya Alame, Erica Resendes, Pratik Kalsaria, Phuong-Khanh J. Nguyen-Trong, Bavana V. Rangan, Michele Roesle, Shuaib Abdullah, Subhash Banerjee, Emmanouil S. Brilakis Source Type: research

Zotarolimus eluting Resolute Integrity versus Everolimus eluting Xience Xpedition stents in the management of very long ( > 30mm) de novo coronary artery stenosis
Procedural and clinical outcomes in patients with very long (>30mm) coronary lesions who underwent stent-based percutaneous coronary interventions is still unfavorable. Therefore, we compared the relative efficacy and safety of resolute zotarolimus-eluting stents (R-ZES) and Xpedition everolimus-eluting stents (X-EES) for patients with de novo very long coronary lesions. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 13, 2016 Category: Cardiology Authors: Soumya Patra, Rabindra Nath Chakraborty, Arindam Pande, Suvro Banerjee, Manabhanjan Jena, Prakash Chandra Mandal, Swapan Kumar De, Aftab Khan, Sankha Suvro Das, Debashish Ghosh, Raja Nag Source Type: research

Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions
The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 11, 2016 Category: Cardiology Authors: Kyle D. Buchanan, M. Chadi Alraies, Alexandre H. Kajita, Toby Rogers, Edward Koifman, Arie Steinvil Tags: Review Source Type: research

Late Breaking Trials from the 2016 American Heart Association's Scientific Sessions
The late breaking trials released at the American Heart Association scientific sessions conference in November in New Orleans, LA covered a wide range of topics, including new devices within the field of heart failure, new registry data on transcatheter aortic valve replacement (TAVR) in intermediate risk patients, and medical management of peripheral arterial disease, coronary artery disease, and hypercholesterolemia. The following review highlights the late breaking trials presented at the conference that will have significant impact on clinical practice. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 11, 2016 Category: Cardiology Authors: Kyle D Buchanan, M Chadi Alraies, Alexandre H Kajita, Toby Rogers, Edward Koifman, Arie Steinvil Source Type: research

More stents, more troubles
We have read with great interest the article entitled “Importance of IVUS in the treatment with retrograde approach of long in-stent chronic total occlusion of ostial right coronary artery: A case report” by Talanas and Garbo [1]. The authors describe their efforts to treat in-stent chronic total occlusion (ISR-CTO) of an ostial right coronary arte ry (RCA) using various approaches (classical antegrade and retrograde techniques and knuckle-wire approach), many types of guiding catheters, and four bioresorbable polymer sirolimus-eluting stents. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - December 5, 2016 Category: Cardiology Authors: Violeta Dinesch, Mircea Buruian Source Type: research

Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place?
The identification of the optimal periprocedural antithrombotic therapy for percutaneous coronary interventions is still a matter of debate [1,2]. On the one hand percutaneous coronary intervention per se induces thrombin generation which makes necessary administration of adjunctive antithrombotic therapy [1,2], on the other hand bleeding complications can significantly influence acute- and long-term survival and morbidity [3]. The ideal antithrombotic medication should have rapid onset of action, predictable dose-dependent effect, quick reversibility, and wide therapeutic window. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 30, 2016 Category: Cardiology Authors: Daniele Giacoppo, Adnan Kastrati Tags: Editorials Source Type: research

Percutaneous treatment of left main disease: Still learning about the optimal PCI strategy
Percutaneous treatment of unprotected left main (ULM) evolved over time and currently it is recommended [1] as an alternative to coronary artery bypass-graft (CABG) in selected patients. (See Fig. 1.) (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 30, 2016 Category: Cardiology Authors: Marco Ancona, Alaide Chieffo Tags: Editorial Source Type: research

Left main occlusion secondary to infective endocarditis vegetation: “the unusual suspect”
We present the case of a patient presented at the Emergency Department with chest pain and cardiogenic shock. The coronary angiography showed a large filling defect in the left main due to a septic coronary embolism. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 29, 2016 Category: Cardiology Authors: Marco Pavani, Federico Conrotto, Fabrizio D'Ascenzo, Maurizio D'Amico, Paolo Centofanti, Fiorenzo Gaita Source Type: research

Influence of Ezetimibe in addition to high-dose Atorvastatin Therapy on Plaque Composition in Patients with ST-segment Elevation Myocardial Infarction assessed by serial
The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 27, 2016 Category: Cardiology Authors: Mikkel Hougaard, Henrik Steen Hansen, Per Thayssen, Lisbeth Antonsen, Anders Junker, Karsten Veien, Lisette Okkels Jensen Source Type: research

Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenases Deficiency After Percutaneous Coronary Intervention: A Reappraisal for clinical and interventional cardiologists
Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has becomes mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences. (Source: Cardiovascul...
Source: Cardiovascular Revascularization Medicine - November 27, 2016 Category: Cardiology Authors: Marco Zuin, Gianluca Rigatelli, Mauro Carraro, Maria Paola Galasso, Fabio Dell'Avvocata, Rossella Paolini, Giovanni Zuliani, Loris Roncon Tags: Mini-review Source Type: research

Transcatheter Therapeutic Conference 2016 — Highlights of Late-breaking Trials
The late-breaking trials presented at the Transcatheter Therapeutic Conference (TCT) 2016 in Washington, DC, covered a wide range of interventional and structural heart technologies and devices, including bioresorbable vascular scaffolds, drug-coated balloons, left atrial appendage closure, neuroprotection, patent foramen ovale closure, and transcatheter aortic valve replacement. In this review, we highlight the major studies presented at the conference that will have a major impact on current clinical practice (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 14, 2016 Category: Cardiology Authors: M. Chadi Alraies, Kyle Buchanan, Arie Steinvil, Toby Rogers, Edward Koifman, Alexandre H. Kajita, Ron Waksman Source Type: research

Transcather Therapeutic Conference 2016 – Highlights of Late-breaking Trials
The late-breaking trials presented at the Transcatheter Therapeutic Conference (TCT) 2016 in Washington, DC, covered a wide range of interventional and structural heart technologies and devices, including bioresorbable vascular scaffolds, drug-coated balloons, left atrial appendage closure, neuroprotection, patent foramen ovale closure, and transcatheter aortic valve replacement. In this review, we highlight the major studies presented at the conference that will have a major impact on current clinical practice. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 14, 2016 Category: Cardiology Authors: M Chadi Alraies, Kyle Buchanan, Arie Steinvil, Toby Rogers, Edward Koifman, Alexandre H Kajita, Ron Waksman Source Type: research

Reply: Time to start implementing lean and six sigma in the catheterization laboratory
We read with interest the brief review by Krittanawong et al., summarizing the data available regarding the implementation of Lean Six Sigma processes in the modern day catheterization laboratories [1]. As pointed out by the authors, these strategies were originally developed in manufacturing industries and aimed to improve process efficiency as well as reduce waste products. As one could easily surmise, Lean and Six Sigma have strongly complementary strengths that could be very useful for a considerable improvement in several healthcare workflow processes. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 8, 2016 Category: Cardiology Authors: Shikhar Agarwal, Kanika Khanna Agarwal, Akhil Parashar, Samir Kapadia Tags: Letter to the Editor Source Type: research

Reply: A Different Kind of Anchor: An Alternative to the Distal Anchoring Technique
The Editorial by Dr. Heuser and Dr. Naqi is very interesting as it describes a further technique that allow to increase the success rate in challenging coronary intervention (PCI) characterized by failure to deliver stents to the target lesion. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - November 8, 2016 Category: Cardiology Authors: Luigi Fiocca, Chiara Bernelli Tags: Letter to the Editor Source Type: research